ROCKVILLE, MD , March 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Margetuximab: Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019; Plans to initiate Phase 2/3 registration-directed, front-line gastric cancer study Enoblituzumab: Encouraging anti-PD-1 combo data supports Phase 2 study initiation in second half of 2019 PD-1

ROCKVILLE, MD , Feb. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Feb. 19, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, February 26, 2019 ,

ROCKVILLE, MD , Feb. 13, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Feb. 12, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public

ROCKVILLE, MD , Feb. 12, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten

Margetuximab improved progression-free survival (PFS) compared to HERCEPTIN® (trastuzumab), when used in combination with chemotherapy in patients with HER2+ metastatic breast cancer BLA submission targeted for second half of 2019 Company to host conference call today at 8:30 AM (ET) ROCKVILLE, MD

ROCKVILLE, MD , Jan. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S.

32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patients Well tolerated in dose escalation and expansion cohorts ROCKVILLE, MD , Jan. 17, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and

Rockville, MD , Jan. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig , M.D., Ph.D.,

ROCKVILLE, MD , Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on December 6 , it received a

Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients Translational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc.

Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing development Expand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to first-in-class dual checkpoint inhibitor, MGD013 Jointly conduct global studies across multiple

ROCKVILLE, MD , Nov. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Nov. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it had presented a poster titled

Enoblituzumab + pembrolizumab combination study data reported: ORRs in anti-PD-1/PD-L1 naïve SCCHN and NSCLC cohorts benchmarked favorably vs. approved anti-PD-1 agents Interim data from Phase 1 dose expansion study of MGA012 (anti-PD-1): objective responses in NSCLC, cervical cancer, endometrial

Margetuximab: Phase 3 SOPHIA study enrollment completed; topline results 1Q 2019 PD-1 franchise: MGD013 cohort expansions initiated; $15 million in MGA012 milestones triggered; MGD019 IND cleared B7-H3 franchise: enoblituzumab oral presentation at SITC ; MGC018 Phase 1 study initiating

Rockville, MD , Oct. 31, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 7, 2018 , the Company will release its financial results for the quarter ended September 30, 2018 . The Company's management team will host a conference call discussing the

ROCKVILLE, MD , Oct. 22, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Sept. 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Rockville, MD , Aug. 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Aug. 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, Md. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and

ROCKVILLE, MD , July 30, 2018 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, August 7, 2018 , the Company will release its financial results for the quarter ended June 30, 2018 . The Company's management team will host a conference call discussing the